Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Ertugliflozin: From Transport Assay to Outcomes
2026-08-27
Ertugliflozin and PF-04971729 offer a precise framework for studying renal glucose reabsorption inhibition. This article connects transport biology, assay design, and cardiovascular outcome interpretation while defining the limits of translational claims.
-
PEGylated Iron Oxide Nanoparticles in the Liver
2026-08-27
This ACS Nano study separates the effects of iron oxide nanoparticle size and PEG chain length on hepatic distribution using 99mTc tracing, SPECT/CT, and primary liver-cell assays. Its finding that hepatocytes and stellate cells can contribute substantially to uptake, while 2K PEG minimizes hepatic accumulation, provides a more cell-resolved framework for nanomedicine design.
-
Elobixibat Hydrate: IBAT Assay Workflows
2026-08-26
Elobixibat hydrate enables target-focused studies of ileal bile acid transport, intestinal motility, and downstream TGR5–GLP-1 signaling. This workflow guide connects formulation, concentration-response testing, translational endpoints, and troubleshooting for constipation, colonoscopy preparation, and metabolic research.
-
Elobixibat Hydrate: From IBAT Biology to Assays
2026-08-26
Elobixibat hydrate is an ileal bile acid transporter inhibitor whose value extends beyond laxation: it offers a mechanistically resolved way to study bile acid delivery, epithelial secretion, motility, and metabolic signaling. This guide translates the core literature into practical assay and interpretation decisions.
-
ACE Inhibitor-Mediated Angioedema: Mechanisms and Care
2026-08-25
Montinaro and Cicardi synthesize the epidemiology, bradykinin-centered pathophysiology, risk modifiers, and treatment uncertainty surrounding ACE inhibitor-mediated angioedema. The review’s practical contribution is to distinguish this adverse reaction from histamine-driven allergy and to clarify why drug withdrawal, airway assessment, and cautious selection of alternative renin–angiotensin system therapy are central to management.
-
E-4031: From hERG Blockade to 3D Arrhythmia Maps
2026-08-25
E-4031 is more than a potent hERG potassium channel blocker: it is a strategic perturbation tool for connecting ion-channel mechanism with tissue-level arrhythmia phenotypes. Combined with shell microelectrode arrays and cardiac organoids, it can help translational researchers move from QT interval prolongation to spatially resolved models of proarrhythmic risk.
-
25-Hydroxycholesterol Reprograms Immunosuppressive TAMs
2026-08-24
Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal lipid sensing to AMPKα–STAT6 signaling in tumor-associated macrophages. The findings suggest that disrupting this axis can improve T-cell surveillance and enhance anti-PD-1 efficacy, while also providing a framework for studying macrophage metabolism in complex tumor models.
-
Pertussis Toxin as a Translational Immune Probe
2026-08-24
Pertussis toxin is more than a classical virulence factor: it is a controlled perturbation tool for interrogating cAMP-linked immune biology. This article connects dendritic-cell signaling, TH17 transcriptional regulation, vascular physiology, and translational assay design while defining the boundaries between mechanistic insight and overinterpretation.
-
Taltirelin Acetate: From Mechanism to Translation
2026-08-23
A translational framework for using Taltirelin acetate across neuroprotection, movement-disorder, itch, sleep-apnea, and formulation research—linking TRHR1 biology to experimental design and bioequivalence strategy.
-
Ibrexafungerp Activity at Vaginal pH
2026-08-22
Sobel and colleagues evaluated Ibrexafungerp, also known as MK 3118, against 187 clinical Candida isolates under neutral and acidic conditions relevant to vulvovaginal candidiasis. Its activity was preserved at pH 4.5, including against fluconazole-resistant Candida albicans and several non-albicans species, supporting further translational study while remaining an in vitro finding.
-
DON Liver Injury: Mitophagy and Nrf2 Signaling
2026-08-22
The reference study identifies overactivated PINK1/Parkin-mediated mitophagy and suppression of the p62-Keap1-Nrf2 defense pathway as coordinated mechanisms of deoxynivalenol-induced liver injury. Its use of mitophagy inhibition, PINK1 silencing, and p62 overexpression provides a mechanistic framework for connecting mitochondrial damage with oxidative stress, inflammation, apoptosis, and lipid dysregulation.
-
Chlorpromazine C6410 for Reliable Cell Assays
2026-08-21
A scenario-driven guide to using Chlorpromazine (SKU C6410) in cell viability, proliferation, cytotoxicity, and hepatic nanoparticle workflows. It explains solvent controls, mechanistic interpretation, product-selection criteria, and the evidence limits of cross-domain applications.
-
Psora 4: A Practical Kv1.3 Blocker Workflow
2026-08-20
Psora 4 supports selective Kv1.3 blockade studies across calcium imaging, electrophysiology, T-cell functional assays, and preclinical inflammation models. This workflow emphasizes compound handling, KCNE4-aware kinetics, effector-memory T-cell readouts, and controls that distinguish target engagement from nonspecific toxicity.
-
RNA Quality as a Strategic Variable in Antiviral Translation
2026-08-20
Mechanistic antiviral studies increasingly depend on RNA workflows that preserve interpretability from enzymatic reaction to translational conclusion. This thought-leadership article connects the prunin–Senecavirus A findings with practical RNA purification strategy, positioning the RNA Clean and Concentrator Kit as a workflow option for reproducible, scalable RNA cleanup.
-
Anagliptin (SK-0403) in Vascular Research
2026-08-19
Anagliptin (SK-0403) combines a well-defined DPP-4 inhibition mechanism with a practical probe for vascular smooth-muscle studies. This workflow connects biochemical potency to rabbit-aorta vasorelaxation while distinguishing Kv channel modulation and SERCA pump regulation from endothelial cyclic-nucleotide signaling.